AbbVie Signs an Exclusive Research and Option to License Agreement with Sosei Heptares Targeting Inflammatory and Autoimmune Diseases
Shots:
- Sosei to receive ~$32M as upfront and ~$377M as option fees- development- and commercial milestones along with royalties on global sales of therapies. AbbVie to get an option to expand the collaboration up to a total of four therapies that modulate GPCR
- Sosei will leverage its StaR technology and GPCR-focused SBDD capabilities and fund R&D activities through the completion of IND-enabling studies. AbbVie may then pay license fees to exercise its exclusive license options and will lead global development and commercialization activities
- In 2016- Sosei collaborated with Allergan targeting Alzheimer’s and other neurological disorders for a total value of ~$3.3B. Additionally- AbbVie completed the acquisition of Allergan last month
Click here to read full press release/ article | Ref: Sosei Heptares | Image: abbvie
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
